EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
12
06
2020
accepted:
13
08
2020
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
18
2
2021
Statut:
ppublish
Résumé
This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-317Subventions
Organisme : Medical Research Council
ID : MR/T02383X/1
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-394.
Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-382.
The GRADE Working Group. In, Vol. 2018. 2018.
Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol 2017; 31: 9-19.
Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol 2017; 31: 20-29.
Sbidian E, Chaimani A, Afach S et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: Cd011535.
Nast A, Gisondi P, Ormerod AD et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-Update 2015-Short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277-2294.
Nast A, Spuls PI, van der Kraaij G et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951-1963.
Elmamoun M, Chandran V. Role of methotrexate in the management of psoriatic arthritis. Drugs 2018; 78: 611-619.
McInnes IB, Nash P, Ritchlin C et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. J Comp Eff Res 2018; 7: 1107-1123.
Mease PJ, Smolen JS, Behrens F et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79: 123-131.
Nash P, McInnes IB, Mease PJ et al. Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison. Rheumatol Ther 2018; 5: 99-122.
Dressler C, Eisert L, Pham PA, Nast A. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol 2019; 33: 1249-1260.
Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009; 68: 1793-1794.
Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12.
Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. J Dtsch Dermatol Ges 2018; 16: 806-813.
Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33: 464-483.
Elmets CA, Leonardi CL, Davis DMR et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80: 1073-1113.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Dermatovenereol 2010; 90: 147-151.
Targan SR, Feagan B, Vermeire S et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. Am J Gastroenterol 2016; 111: 1599-1607.
Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693-1700.
Armstrong A, Paul C, Puig L et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther 2019; 10(1): 133-150.
Deodhar A, Mease PJ, McInnes IB et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthrit Res Ther 2019; 21: 111.
Feagan BG, Sandborn WJ, D'Haens G et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017; 389: 1699-1709.
Reich K, Armstrong AW, Langley RG et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831-839.
Whitlock SM, Enos CW, Armstrong AW et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018; 78: 383-394.
Feagan BG, Panes J, Ferrante M et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol 2018; 3: 671-680.
Visvanathan S, Baum P, Salas A et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn's disease: results from a randomised phase II biopsy sub-study. J Crohns Colitis 2018; 12: 1170-1179.
Grossberg LB. A case report of successful treatment of Crohn's disease and psoriasis with guselkumab. Inflamm Bowel Dis 2019; 25: e84.
Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease. J Dermatol Treat 2019; 1-3.
Danese S, Neurath M, Kopon A et al. OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. J Crohns Colitis 2018; 12: S004-S005.
Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2014; 2014: Cd006884.
McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2014; 2014: Cd003459.
Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; 2014: Cd006618.
Herfarth H, Barnes EL, Valentine JF et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology 2018; 155(1098-108): e9.
Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018; 57: 1521-1532.
Laharie D, Bourreille A, Branche J et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018; 67: 237-243.
Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 1332-1343.
Vaengebjerg S, Skov L, Egeberg A, Prevalence LND. Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol 2020; 156: 421.
Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 2018; 178: 103-113.
Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol 2017; 176: 643-649.
Holroyd CR, Seth R, Bukhari M et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 2019; 58: e3-e42.
Luo X, Deng C, Fei Y et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. Semin Arthritis Rheum 2019; 48: 626-631.
Kim SC, Schneeweiss S, Liu J et al. Biologic Disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: a cohort study. Arthritis Rheumatol (Hoboken, N.J.) 2016; 68: 2106-2113.
Mercer LK, Low AS, Galloway JB et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 2013; 72: 143-144.
Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol 2019; 53: e1-e11.
Scott FI, Mamtani R, Brensinger CM et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 2016; 152: 164-172.
Shelton E, Laharie D, Scott FI et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2016; 151: 97-109.e4.
Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009-2012. JAMA Dermatol 2016; 152: 73-79.
Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. Br J Dermatol 2019; 180: 116-121.
Fleming P, Roubille C, Richer V et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015; 29: 1063-1070.
Tribo MJ, Turroja M, Castano-Vinyals G et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Dermatovenereol 2019; 99: 417-422.
Abbott R, Whear R, Nikolaou V et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res 2015; 79: 175-184.
Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P. Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermatol Treat 2018; 29: 806-811.
Gordon KB, Armstrong AW, Han C et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940-1949.
Griffiths CEM, Fava M, Miller AH et al. Impact of Ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom 2017; 86: 260-267.
Schmieder A, Poppe M, Hametner C et al. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study. Arch Dermatol Res 2015; 307: 413-424.
Kim SJ, Park MY, Pak K et al. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and (18)fluorodeoxyglucose (FDG) positron emission tomography (PET). J Dermatol Treat 2018; 29: 761-768.
Strober B, Gooderham M, de Jong E et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70-80.
Arican O, Sasmaz S, Ozbulut O. Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venereol 2006; 20: 464-465.
Henderson CA, Highet AS. Depression induced by etretinate. BMJ 1989; 298: 964.
Hayes J, Koo J. Depression and acitretin: a true association or a class labeling? J Drugs Dermatol 2011; 10: 409-412.
Starling J, 3rd, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005; 4: 690-696.
European Medicines Agency. Retinoid-containing medicinal products. In. 2018.
European Medicines Agency. Acitretin SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 22 0ct 2019.
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318-1328.
Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273-286.
Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther 2019; 19: 287-292.
European Medicines Agency. Kyntheum SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 25 sep 2017.
Crowley J, Thaci D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >/=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77(310-7): e1.
Kavanaugh A, Gladman DD, Edwards CJ et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther 2019; 21: 118.
European Medicines Agency. Otezla (apremilast): New important advice regarding suicidal ideation and behaviour. In: Celgene Europe Limited. 2016.
European Medicines Agency. Otezla SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 10 Sep 2019.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84-91.
Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr 2019; 13: 1405-1412.
Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 783-793.
Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol 2014; 70: 691-698.
Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837-844.
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
Dehpouri T, Rokni GR, Narenjbon NA et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Rep 2019; 11: 7965.
Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report. Postepy Dermatol Alergol 2018; 35: 53-59.
Wu JJ, Liu L, Asgari MM et al. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. J Eur Acad Dermatol Venereol 2014; 28: 1380-1387.
Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118.
Singh JA, Guyatt G, Ogdie A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res 2019; 71: 2-29.
Gisondi P, Cazzaniga S, Chimenti S et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013; 27: 30-41.
Cotovio P, Neves M, Rodrigues L et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. Transplant Proc 2013; 45: 1079-1083.
Sato T, Inagaki A, Uchida K et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003; 76: 1320-1326.
Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011; 21: 916-920.
Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.
Renzo LD, Saraceno R, Schipani C et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 2011; 24: 446-451.
Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol 2013; 168: 1124-1127.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27-40.
da Silva BS, Bonfa E, de Moraes JC et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals 2010; 38: 567-569.
Costa L, Caso F, Atteno M et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33: 833-839.
Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461-465.
Kofoed K, Clemmensen A, Mikkelsen UR, Simonsen L, Andersen O, Gniadecki R. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. Arch Dermatol 2012; 148: 1089-1091.
Campanati A, Ganzetti G, Di Sario A et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-846.
Marra M, Campanati A, Testa R et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731-736.
Pina T, Armesto S, Lopez-Mejias R et al. Anti-TNF-alpha therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol 2015; 29: 1325-1330.
Al-Mutairi N, Shabaan D. Effects of tumor necrosis factor alpha inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. Cutis 2016; 97: 235-241.
Gerdes S, Pinter A, Papavassilis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol 2019; 34(3): 533-541.
Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr 2008; 88: 1242-1247.
Jensen P, Zachariae C, Christensen R et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol 2013; 149: 795-801.
Naldi L, Conti A, Cazzaniga S et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol 2014; 170: 634-642.
Ford AR, Siegel M, Bagel J et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: a systematic review. JAMA Dermatol 2018; 154: 934-950.
Pinter A, Gerdes S, Papavassilis C, Reinhardt M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J Dermatol Treat 2020; 31: 769-775.
Koenig AS, Szumski A, Pedersen R, Robertson D. Impact of Etanercept Therapy on Glycemical Control in a Cohort of Psoriatic Patients: The PRISTINE Trial. In. 2010.
Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging 2014; 31: 233-238.
Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-949.
Hong JR, Lee YW, Choe YB, Ahn KJ. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice. Dermatol Ther 2019; 32: e12875.
Knuuti J, Wijns W, Saraste A et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407-477.
Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315-2381.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188.
Boehncke W-H, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. J Rheumatol 2011; 38: 567-571.
Kimball AB, Szapary P, Mrowietz U et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 67: 76-85.
Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol 2011; 131: 1159-1166.
Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-2346.
Gaeta M, Castelvecchio S, Ricci C, Pigatto P, Pellissero G, Cappato R. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. Int J Cardiol 2013; 168: 2282-2288.
Kaiser H, Abdulla J, Henningsen KMA, Skov L, Hansen PR. Coronary artery disease assessed by computed tomography in patients with psoriasis: a systematic review and meta-analysis. Dermatology 2019; 235: 478-487.
Davidovici BB, Sattar N, Prinz JC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-1796.
Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-289.
Chappe SG, Roenigk HH, Miller AJ, Beeaff DE, Tyrpin L. The effect of photochemotherapy on the cardiovascular system. J Am Acad Dermatol 1981; 4: 561-566.
Hugh J, Van Voorhees AS, Nijhawan RI et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014; 70: 168-177.
Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 1999; 41: 7.
Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 2010: CD007893.
Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
Prodanovich S, Prodanowich S, Ma F et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
Westlake SL, Colebatch AN, Baird J et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2010; 49: 295-307.
Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480-489.
Ahlehoff O, Skov L, Gislason G et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015; 29: 1128-1134.
Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Tercedor-Sanchez J, Arias-Santiago S. Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 1492-1498.
Imam F, Al-Harbi NO, Al-Harbi MM et al. Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-kappaB signaling pathways. Pharmacol Rep 2018; 70: 993-1000.
Peters MJL, Watt P, Cherry L et al. Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann Rheum Dis 2010; 69: 1687-1690.
Strober B, Teller C, Yamauchi P et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330.
Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013; 168: 749-755.
Eder L, Joshi AA, Dey AK et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol (Hoboken, N.J.) 2018; 70: 408-416.
Gelfand JM, Shin DB, Alavi A et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol 2020; 140: 85-93.e2.
Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006; 26: 1125-1131.
Tam LS, Li EK, Shang Q et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011; 70: 705-706.
Pina T, Corrales A, Lopez-Mejias R et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol 2016; 43: 1267-1272.
von Stebut E, Reich K, Thaci D et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 2019; 139: 1054-1062.
Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066-1073.
Leisner MZ, Lindorff Riis J, Gniadecki R, Iversen L, Olsen M. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. J Eur Acad Dermatol Venereol 2018; 32: 2185-2190.
Ryan C, Leonardi CL, Krueger JG et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-871.
Wu JJ, Poon K-YT, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244-1250.
Ahlehoff O, Skov L, Gislason G et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197-204.
Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol 2017; 76: 81-90.
Reich K, Langley RG, Lebwohl M et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-872.
Papp KA, Griffiths CE, Gordon K et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-854.
Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2017; 176: 890-901.
Champs B, Degboe Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD open 2019; 5: e000763.
Rungapiromnan W, Mason KJ, Lunt M et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol 2020; 34: 769-778.
Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol 2019; 155: 700-707.
Ponikowski P, Voors AA, Anker SD et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Espanola Cardiol (English ed.) 2016; 69: 1167.
Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999; 14: 206-210.
Deswal A, Bozkurt B, Seta Y et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-3226.
Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002; 4: 559-561.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140.
Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2011: CD008794.
Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ 2013; 347: f5961.
Garcia-Doval I, Carretero G, Vanaclocha F et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
Ormerod AD, Campalani E, Goodfield MJ, Unit BADCS. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-963.
Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
Carretero G, Ribera M, Belinchon I et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas Dermosifiliogr 2013; 104: 598-616.
Bath-Hextall F, Leonardi-Bee J, Somchand N, Webster A, Delitt J, Perkins W. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Cochrane Database Syst Rev 2007; 4: CD005414.
Stuck AE, Brindley CJ, Busslinger A, Frey FJ. Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis. Br J Clin Pharmacol 1989; 27: 301-304.
Chimenti MS, Gramiccia T, Saraceno R et al. Apremilast for the treatment of psoriasis. Expert Opin Pharmacother 2015; 16: 2083-2094.
Cada DJ, Levien TL, Baker DE. Dimethyl fumarate. Hosp Pharm 2013; 48: 668-679.
Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 2010; 302: 531-538.
Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009; 129: 231-234.
Maza A, Montaudie H, Sbidian E et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011; 25(Suppl 2): 19-27.
Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 2013; 37: 602-612.
Chadban SJ, Barraclough KA, Campbell SB et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients. Nephrology 2012; 17: 204-214.
Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40.
Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998; 57: 110-113.
Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995; 22: 218-223.
Willner N, Storch S, Tadmor T, Schiff E. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. Eur J Clin Pharmacol 2014; 70: 261-263.
Le Boedec M, Marhadour T, Devauchelle-Pensec V et al. Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany). Semin Arthritis Rheum 2013; 42: 474-481.
Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000; 13: 313-326.
Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
Tan TC, Robinson PJ. Mechanisms of calcineurin inhibitor-induced neurotoxicity. Transpl Rev 2006; 20: 49-60.
Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 2013; 13: 2426-2432.
Thompson CB, Sullivan KM, June CH, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesemia. Lancet 1984; 2: 1116-1120.
Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 2013; 47: 1697-1702.
van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368: 1658-1659.
Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368: 1657-1658.
Stoppe M, Thoma E, Liebert UG et al. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 2014; 261: 1021-1024.
Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med 2013; 368: 1659-1661.
Buttmann M, Stoll G. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013; 369: 1081.
Bartsch T, Rempe T, Wrede A et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 2015; 78: 501-514.
Nieuwkamp DJ, Murk JL, van Oosten BW et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015; 372: 1474-1476.
Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 2015; 15: 108.
Hoepner R, Faissner S, Klasing A et al. Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. Neurol Neuroimmunol Neuroinflamm 2015; 2: e85.
Paudyal B, Viets R, Skliut M. A case of low-dose oral methotrexate-induced reversible neurotoxicity. AJNR Am J Neuroradiol 2010; 31: E77.
Sommer WH, Ganiere V, Gachoud D et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. Scand J Rheumatol 2008; 37: 306-309.
Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014; 13: 54-58.
van Oosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
Gregory AP, Dendrou CA, Attfield KE et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; 488: 508-511.
Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatol Treat 2013; 24: 38-49.
Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 2011; 7: 165-172.
Kay J, Fleischmann R, Keystone E et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis 2015; 74: 538-546.
Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C. Extensive and severe CNS demyelination associated with golimumab therapy. J Neurol 2016; 263: 1869-1871.
Barreras P, Mealy MA, Pardo CA. TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. J Neurol Sci 2017; 373: 303-306.
Hare NC, Hunt DP, Venugopal K et al. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. QJM 2014; 107: 51-55.
Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNFalpha therapy: A case report. Mult Scler Relat Disord 2018; 26: 37-39.
Boggs JME, Barnes L. Demyelination during anti-tumour necrosis factor therapy for psoriasis. Clin Exp Dermatol 2018; 43: 577-578.
Honda Y, Otsuka A, Egawa G et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-alpha therapy in psoriatic arthritis. Eur J Dermatol 2015; 25: 487-488.
Motuzova Y, Di Sapio A, Capobianco M et al. Peculiar cytological cerebrospinal fluid pattern in a case of encephalomyelitis during anti-tumor necrosis factor-alpha therapy. Neurol Ther 2015; 4: 53-60.
Theibich A, Dreyer L, Magyari M, Locht H. Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. Clin Rheumatol 2014; 33: 719-723.
Escalas J, Knopfel N, Martin-Santiago A, Calles C. Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis. J Am Acad Dermatol 2014; 70: e17-e18.
Sarathchandran P, Alboudi A, AlSuwaidi R, Almadani AA. Iatrogenic transverse myelitis in a patient with rheumatoid arthritis. BMJ Case Rep 2019; 12: e227584.
Baumer FM, Ouahed J, Verhave M, Rivkin MJ. Fatal central nervous system disease following first infliximab infusion in a child with inflammatory bowel disease. Pediatr Neurol 2016; 57: 91-94.
Signore SC, Brauns B, Schutze G et al. Infliximab-associated chronic inflammatory central nervous system disease and peroneal nerve injury in a psoriatic patient refractory to treatment: case report with 10-year follow-up. Case Rep Neurol 2018; 10: 12-17.
Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis 2010; 69: 1691-1693.
Ramiro S, Gaujoux-Viala C, Nam JL et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014; 73: 529-535.
Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66: 490-497.
Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. J Crohns Colitis 2014; 8: 1138-1139.
Fukushima T, Nakajima K, Nozawa H et al. [A case of Crohn's disease complicated by Guillain-Barre syndrome during ustekinumab therapy]. Nihon Shokakibyo Gakkai Zasshi 2019; 116: 324-329.
Acer E, Igrek A, Erdogan HK, Saracoglu ZN. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre. Dermatol Ther 2020; 33: e13224.
Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011; 147: 1197-1202.
Kolbinger F, Huppertz C, Mir A, Padova FD. IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous system. Curr Drug Targets 2016; 17: 1882-1893.
Havrdova E, Belova A, Goloborodko A et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol 2016; 263: 1287-1295.
Diebold M, Muller S, Derfuss T, Decard BF. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. Mult Scler Relat Disord 2019; 31: 38-40.
Assefa GT, Kaneko S, Oguro H, Morita E. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. J Dermatol 2019; 46: e112-e113.
Venturini M, Zanca A, Venturuzzo A et al. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. J Eur Acad Dermatol Venereol 2019; 34: e110-e112.
Cortese A, Lucchetti R, Altobelli A et al. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. Mult Scler Relat Disord 2019; 35: 193-195.
Ebers GC, Bulman DE, Sadovnick AD et al. A population-based study of multiple sclerosis in twins. N Engl J Med 1986; 315: 1638-1642.
Siva A. Asymptomatic MS. Clin Neurol Neurosurg 2013; 115(Suppl 1): S1-5.
Tang KT, Chen YM, Chang SN, Lin CH, Chen DY. Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: Real-world data from a nationwide cohort study in Taiwan. J Am Acad Dermatol 2018; 79: 652-658.
Lewinsohn DM, Leonard MK, LoBue PA et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 2017; 64: 111-115.
Desai N, Raste Y, Cooke NT, Harland CC. QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy. Br J Dermatol 2008; 158: 1137-1138.
Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41(Suppl 3): S199-203.
World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. In: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization (c) World Health Organization 2018. 2018.
Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Family Phys 2005; 72: 1761-1768.
Christensen WI. Genitourinary tuberculosis: review of 102 cases. Medicine 1974; 53: 377-390.
Simon HB, Weinstein AJ, Pasternak MS, Swartz MN, Kunz LJ. Genitourinary tuberculosis. Clinical features in a general hospital population. Am J Med 1977; 63: 410-420.
National Collaborating Centre for Chronic C, Centre for Clinical Practice at, Nice. National Institute for Health and Clinical Excellence: Guidance. In: Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. London: National Institute for Health and Clinical Excellence (UK) Royal College of Physicians of London. Updated text, Copyright (c) 2011, National Institute for Health and Clinical Excellence. 2011.
Schaberg T, Bauer T, Brinkmann F et al. Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP). Pneumologie (Stuttgart, Germany) 2017; 71: 325-397.
Doherty SD, Van Voorhees A, Lebwohl MG et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-217.
Arias-Guillen M, Sanchez Menendez MM, Alperi M et al. High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results? Semin Arthritis Rheum 2018; 48: 538-546.
Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017; 2017: 8909834.
Snast I, Bercovici E, Solomon-Cohen E et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review. Am J Clin Dermatol 2019; 20: 483-491.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol 2019; 80: 43-53.
Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5: ofy174.
Fox RJ, Kita M, Cohan SL et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014; 30: 251-262.
Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 2019; 18: 415-425.
Crowley J, Thaci D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77: 310-317.e1.
Baddley JW, Cantini F, Goletti D et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). Clin Microbiol Infect 2018; 24(Suppl 2): S10-s20.
Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014; 91: 47-55.
Winthrop KL, Mariette X, Silva JT et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24(Suppl 2): S21-s40.
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676-1684.
Lebwohl MG, Papp KA, Marangell LB et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2018; 78: 81-89.e5.
Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650-661.
Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996; 35: 169-172.
Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005; 141: 601-606.
Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol 2016; 175: 464-472.
Yang Y-W, Chen C-S, Chen Y-H, Lin H-C. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol 2011; 64: 71-77.
Lima XT, Janakiraman V, Hughes MD, Kimball AB. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol 2012; 132: 85-91.
Bandoli G, Johnson DL, Jones KL et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 2010; 163: 334-339.
European Medicines Agency. Acitretin 25mg Capsules - Summary of Product Characteristics (SmPC) - (emc). In.
European Medicines Agency. Otezla 30 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). In.
Rademaker M, Agnew K, Andrews M et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018; 59: 86-100.
Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 2018; 11: 987-998.
European Medicines Agency. Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). In.
van der Kraaij GE, Balak DMW, Busard CI et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31-42.
European Medicines Agency. Skilarence 30 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC) - (emc). In.
Mrowietz U, Barker J, Boehncke WH et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol 2018; 32(Suppl 3): 3-14.
Verberne EA, de Haan E, van Tintelen JP, Lindhout D, van Haelst MM. Fetal methotrexate syndrome: A systematic review of case reports. Reprod Toxicol 2019; 87: 125-139.
European Medicines Agency. Methotrexate 2.5mg Tablets - Summary of Product Characteristics (SmPC) - (emc). In.
European Medicines Agency. Nordimet - EPAR. 2016.
Warren RB, Weatherhead SC, Smith CH et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016; 175: 23-44.
Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628-636.
Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-233.
Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36: 248-255.
Pottinger E, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol 2018; 178: 95-102.
Ferrante M, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 2014; 13: 255-266.
Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292. quiz e24.
Mariette X, Förger F, Abraham B et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77: 228-233.
Clowse ME, Förger F, Hwang C et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76: 1890-1896.
Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017; 26: 1109-1118.
Burmester GR, Landewé R, Genovese MC et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76: 414-417.
Bröms G, Granath F, Stephansson O, Kieler H. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment. Scand J Gastroenterol 2016; 51: 1462-1469.
Bröms G, Granath F, Ekbom A et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol 2016; 14: 234-241.e1-5.
Luu M, Benzenine E, Doret M et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National health insurance database (EVASION). Am J Gastroenterol 2018; 113: 1669-1677.
Casanova MJ, Chaparro M, Domènech E et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433-440.
Cooper WO, Cheetham TC, Li D-K et al. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Arthritis Rheumatol (Hoboken, N.J.) 2014; 66: 444-450.
Weber-Schoendorfer C, Oppermann M, Wacker E et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015; 80: 727-739.
Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014; 43: 78-84.
Schnitzler F, Fidder H, Ferrante M et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-1854.
Seirafi M, de Vroey B, Amiot A et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40: 363-373.
Verstappen SMM, King Y, Watson KD, Symmons DPM, Hyrich KL. Bsrbr Control Centre Consortium BSRBR. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 823-826.
Clowse MEB, Scheuerle AE, Chambers C et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol (Hoboken, N.J.) 2018; 70: 1399-1407.
Parsch EM, Ruzicka T, Przybilla B, Schill WB. Andrological investigations in men treated with acitretin (Ro 10-1670). Andrologia 1990; 22: 479-482.
Geiger JM, Walker M. Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane? Dermatology (Basel) 2002; 205: 105-107.
Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum 2019; 48: 911-920.
Semet M, Paci M, Saïas-Magnan J et al. The impact of drugs on male fertility: a review. Andrology 2017; 5: 640-663.
Egeberg A, Gislason GH, Nast A. Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception-a Danish population-based cohort study. J Invest Dermatol 2017; 137: 1790-1792.
Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol 2006; 31: 138-140.
Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215-217.
El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979; 3: 177-179.
Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatologica 1977; 154: 78-84.
Eck LK, Jensen TB, Mastrogiannis D et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. Obstet Gynecol 2017; 129: 707-714.
Winter RW, Larsen MD, Magnussen B, Friedman S, Kammerlander H, Nørgård BM. Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study. Reprod Toxicol 2017; 74: 219-223.
Friedman S, Larsen MD, Magnussen B, Jølving LR, de Silva P, Nørgård BM. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study. Reprod Toxicol 2017; 73: 196-200.
Puchner R, Danninger K, Puchner A, Pieringer H. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 2012; 30: 765-767.
Wagner N, Assmus F, Arendt G et al. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2019; 62: 494-515.
Papp KA, Haraoui B, Kumar D et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutaneous Med Surg 2019; 23: 50-74.
European Medicines Agency. Tremfya [Tremfya: EPAR - Product Information]. In. 2017.
European Medicines Agency. Skyrizi - EMEA/H/C/004759 - IA/0006. In. 2019.
European Medicines Agency. Stelara [INN-Ustekinumab: EPAR - Product Information]. In. 2009.
European Medicines Agency. IlumetriTM (Tildrakizumab) Summary of product characteristics. In. 2019.
Goss SL, Klein CE, Jin Z et al. Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO trial. Clin Ther 2018; 40: 309-319.
Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45: 1128-1134.
Van der Kraaij GE. EADV Congress Poster, FC02.06.
Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K. Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach. J Eur Acad Dermatol Venereol 2021; 35: 329-337.